• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5073861)   Today's Articles (184)
For: Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY, Xu CR, Massey D, Kim M, Shi Y, Geater SL. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:213-22. [PMID: 24439929 DOI: 10.1016/s1470-2045(13)70604-1] [Citation(s) in RCA: 1569] [Impact Index Per Article: 142.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Number Cited by Other Article(s)
1
Chen Z, Gong J, Chen J, Yang L, Hu S, Chen L, Lu H. Clinical outcomes of EGFR-TKI in advanced lung squamous cell carcinoma and EGFR-TKI remodel tumor immune microenvironment. Ann Med 2025;57:2488109. [PMID: 40193238 PMCID: PMC11980191 DOI: 10.1080/07853890.2025.2488109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2024] [Revised: 09/04/2024] [Accepted: 02/28/2025] [Indexed: 04/09/2025]  Open
2
Ji H, Zhang L, Ye L. Exosome, an important transmitter in the drug resistance of non-small cell lung cancer. Front Oncol 2025;15:1539047. [PMID: 40444086 PMCID: PMC12119617 DOI: 10.3389/fonc.2025.1539047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2024] [Accepted: 04/28/2025] [Indexed: 06/02/2025]  Open
3
Miyata M, Hayashi H. Current treatment landscape for patients with non-small cell lung cancer with common EGFR mutations. Respir Investig 2025;63:576-584. [PMID: 40328075 DOI: 10.1016/j.resinv.2025.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2025] [Revised: 04/14/2025] [Accepted: 04/22/2025] [Indexed: 05/08/2025]
4
Gomez-Randulfe I, Monaca F, Planchard D, Bria E, Califano R. Evolving treatment for advanced non-small cell lung cancer harbouring common EGFR activating mutations. Crit Rev Oncol Hematol 2025;212:104762. [PMID: 40324662 DOI: 10.1016/j.critrevonc.2025.104762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2025] [Revised: 04/26/2025] [Accepted: 05/01/2025] [Indexed: 05/07/2025]  Open
5
Wang S, Xia Y, Qian Y, Pan W, Huang P, Jin N, Li X, Xu C, Liu D, Zhao G, Fang Y, Nicot C, Gao Q. PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor. Drug Resist Updat 2025;81:101247. [PMID: 40328191 DOI: 10.1016/j.drup.2025.101247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2024] [Revised: 04/15/2025] [Accepted: 04/16/2025] [Indexed: 05/08/2025]
6
Miura S, Tanaka H, Misumi T, Yoshioka H, Tokito T, Fukuhara T, Sato Y, Shiraishi Y, Naoki K, Akamatsu H, Yamaguchi O, Yokoyama T, Kuyama S, Nishino K, Furuya N, Kurata T, Kato T, Ikeda S, Horinouchi H, Ichihara E, Mori M, Takiguchi Y, Tanaka K, Goto Y, Okamoto H. Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834. J Clin Oncol 2025:JCO2402007. [PMID: 40239133 DOI: 10.1200/jco-24-02007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2024] [Revised: 02/20/2025] [Accepted: 03/03/2025] [Indexed: 04/18/2025]  Open
7
Shi Y, Guo Y, Li X, Wu L, Chen Z, Yang S, Bi M, Zhao Y, Yao W, Yu H, Wang K, Zhao W, Sun M, Zhang L, He Z, Lin Y, Shi J, Zhu B, Wang L, Pan Y, Shi H, Sun S, Wen M, Zhou R, Guo S, Han Z, Yi T, Zhang H, Cang S, Yu Z, Zhong D, Cui J, Fang J, Gao J, Li M, Ma R, Jiang M, Qin J, Shu Y, Ye F, Hu S, Li W, Lu H, Yang M, Yi S, Zhang Y, Fan Y, Ji H, Liu Z, Wang H, Zhou X, Zhang D, Peng J, Shen H, Gao F, Wang T, Zhou A. Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study. THE LANCET. RESPIRATORY MEDICINE 2025;13:327-337. [PMID: 39914443 DOI: 10.1016/s2213-2600(24)00417-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/11/2024] [Revised: 12/02/2024] [Accepted: 12/10/2024] [Indexed: 03/17/2025]
8
Mei T, Wang T, Xu T, Zhou Q. Comparing the Effectiveness and Safety of First-line Interventions in Patients With Advanced Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer, With Particular Focus on Brain Metastatic Status: A Systematic Review and Network Meta-analysis. Clin Oncol (R Coll Radiol) 2025;40:103776. [PMID: 39951884 DOI: 10.1016/j.clon.2025.103776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2024] [Revised: 01/21/2025] [Accepted: 01/28/2025] [Indexed: 02/17/2025]
9
Liu X, Wang P, Liu G. NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy. Clin Transl Oncol 2025;27:1529-1538. [PMID: 39304598 PMCID: PMC12000150 DOI: 10.1007/s12094-024-03735-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2024] [Accepted: 09/11/2024] [Indexed: 09/22/2024]
10
Uehara Y, Izumi H, Kobayashi IS, Matsumoto S, Hosomi Y, Okuno T, Sugisaka J, Takase N, Taima K, Sasaki S, Teranishi S, Miyamoto S, Mori M, Nakashima C, Asano S, Oi H, Sakai T, Shibata Y, Udagawa H, Sugiyama E, Nosaki K, Umemura S, Zenke Y, Yoh K, Ikeda S, Costa DB, Kobayashi SS, Goto K. Efficacy of EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry). Lung Cancer 2025;202:108479. [PMID: 40088581 DOI: 10.1016/j.lungcan.2025.108479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2025] [Revised: 02/18/2025] [Accepted: 03/01/2025] [Indexed: 03/17/2025]
11
Galeș LN, Păun MA, Butnariu I, Simion L, Manolescu LSC, Trifănescu OG, Anghel RM. Next-Generation Sequencing in Oncology-A Guiding Compass for Targeted Therapy and Emerging Applications. Int J Mol Sci 2025;26:3123. [PMID: 40243903 PMCID: PMC11988731 DOI: 10.3390/ijms26073123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2025] [Revised: 03/17/2025] [Accepted: 03/21/2025] [Indexed: 04/18/2025]  Open
12
Romaniello D, Morselli A, Marrocco I. Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer. Int J Mol Sci 2025;26:2957. [PMID: 40243603 PMCID: PMC11988377 DOI: 10.3390/ijms26072957] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2025] [Revised: 03/22/2025] [Accepted: 03/23/2025] [Indexed: 04/18/2025]  Open
13
Wang QA, Tsai IL, Lin CY, Su PL, Lin CC, Chang JWC, Huang CY, Fang YF, Chang CF, Kuo CHS, Hsu PC, Yang CT, Wu CE. Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study. Ther Adv Med Oncol 2025;17:17588359251321901. [PMID: 40093976 PMCID: PMC11907550 DOI: 10.1177/17588359251321901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2024] [Accepted: 02/04/2025] [Indexed: 03/19/2025]  Open
14
Shi J, Liu X, Gao M, Yu J, Chai T, Jiang Y, Li J, Zhang Y, Wu L. Adverse event profiles of EGFR-TKI: network meta-analysis and disproportionality analysis of the FAERS database. Front Pharmacol 2025;16:1519849. [PMID: 40135231 PMCID: PMC11933087 DOI: 10.3389/fphar.2025.1519849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2024] [Accepted: 02/17/2025] [Indexed: 03/27/2025]  Open
15
Wei JR, Lu MY, Wei TH, Fleishman JS, Yu H, Chen XL, Kong XT, Sun SL, Li NG, Yang Y, Ni HW. Overcoming cancer therapy resistance: From drug innovation to therapeutics. Drug Resist Updat 2025;81:101229. [PMID: 40081221 DOI: 10.1016/j.drup.2025.101229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2024] [Revised: 02/18/2025] [Accepted: 03/03/2025] [Indexed: 03/15/2025]
16
Nie X, Zou M, Song C, Zhang P, Ma D, Cui D, Cheng G, Li L. Survival impact and risk factors of skeletal muscle loss during first-line EGFR-TKIs therapy in advanced lung adenocarcinoma patients. BMC Cancer 2025;25:393. [PMID: 40038684 PMCID: PMC11881361 DOI: 10.1186/s12885-025-13775-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2024] [Accepted: 02/19/2025] [Indexed: 03/06/2025]  Open
17
Liu JY, Wang SZ, Yuan HQ, Li JL, Xing PY. Patients with non‑small cell lung cancer with the exon 21 L858R mutation: From distinct mechanisms to epidermal growth factor receptor tyrosine kinase inhibitor treatments (Review). Oncol Lett 2025;29:109. [PMID: 39776649 PMCID: PMC11704875 DOI: 10.3892/ol.2024.14855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2024] [Accepted: 11/01/2024] [Indexed: 01/11/2025]  Open
18
Yin J, Huang J, Ren M, Tang R, Xie L, Xue J. A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer. CANCER PATHOGENESIS AND THERAPY 2025;3:135-146. [PMID: 40182124 PMCID: PMC11963207 DOI: 10.1016/j.cpt.2024.06.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/13/2024] [Revised: 06/11/2024] [Accepted: 06/18/2024] [Indexed: 04/05/2025]
19
Lee CY, Lee SW, Hsu YC. Drug Resistance in Late-Stage Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer Patients After First-Line Treatment with Tyrosine Kinase Inhibitors. Int J Mol Sci 2025;26:2042. [PMID: 40076686 PMCID: PMC11900297 DOI: 10.3390/ijms26052042] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2025] [Revised: 02/06/2025] [Accepted: 02/19/2025] [Indexed: 03/14/2025]  Open
20
Hasan N, Nagasaka M. Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer. Expert Rev Respir Med 2025:1-10. [PMID: 39965618 DOI: 10.1080/17476348.2025.2467338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2024] [Revised: 01/18/2025] [Accepted: 02/11/2025] [Indexed: 02/20/2025]
21
Tang T, Luo J, Zhang D, Lu Y, Liao W, Zhang J. Innovative design and potential applications of covalent strategy in drug discovery. Eur J Med Chem 2025;284:117202. [PMID: 39756145 DOI: 10.1016/j.ejmech.2024.117202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2024] [Revised: 12/19/2024] [Accepted: 12/21/2024] [Indexed: 01/07/2025]
22
Kenmotsu H. Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for EGFR-Mutated Non-Small Cell Lung Cancer: Old or New Regimen? J Clin Oncol 2025;43:369-372. [PMID: 39393033 DOI: 10.1200/jco-24-01921] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2024] [Revised: 09/05/2024] [Accepted: 09/05/2024] [Indexed: 10/13/2024]  Open
23
Decoster L, Camidge DR, Fletcher JA, Addeo A, Greystoke A, Kantilal K, Game LB, Kanesvaran R, Gomes F. Targeted therapy for older patients with an oncogene driven non-small cell lung cancer: Recommendations from a SIOG expert group. Lung Cancer 2025;200:108087. [PMID: 39826441 DOI: 10.1016/j.lungcan.2025.108087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2024] [Accepted: 01/12/2025] [Indexed: 01/22/2025]
24
Zhou F, Guo H, Xia Y, Le X, Tan DSW, Ramalingam SS, Zhou C. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol 2025;22:95-116. [PMID: 39614090 DOI: 10.1038/s41571-024-00971-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/15/2024] [Indexed: 12/01/2024]
25
Popat S, Januszewski A, O'Brien M, Ahmad T, Lewanski C, Dernedde U, Jankowska P, Mulatero C, Shah R, Hicks J, Geldart T, Cominos M, Gray G, Spicer J, Bell K, Roitt S, Morris C, Ngai Y, Hughes L, Hackshaw A, Wilson W. Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy. Br J Cancer 2025;132:245-252. [PMID: 39639088 PMCID: PMC11790930 DOI: 10.1038/s41416-024-02901-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2024] [Revised: 10/30/2024] [Accepted: 10/31/2024] [Indexed: 12/07/2024]  Open
26
Zhang M, Sun L. First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis. Front Oncol 2025;14:1498518. [PMID: 39882445 PMCID: PMC11774708 DOI: 10.3389/fonc.2024.1498518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2024] [Accepted: 11/27/2024] [Indexed: 01/31/2025]  Open
27
de Moraes FCA, de Oliveira Rodrigues ALS, Pasqualotto E, Cassemiro JF, Choque JWL, Burbano RMR. Ethnic disparities in survival and progression among EGFR-mutated adenocarcinoma of lung cancer patients treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. Clin Transl Oncol 2025:10.1007/s12094-024-03843-4. [PMID: 39797945 DOI: 10.1007/s12094-024-03843-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2024] [Accepted: 12/26/2024] [Indexed: 01/13/2025]
28
Torresan S, Bortolot M, De Carlo E, Bertoli E, Stanzione B, Del Conte A, Spina M, Bearz A. Matters of the Heart: Cardiotoxicity Related to Target Therapy in Oncogene-Addicted Non-Small Cell Lung Cancer. Int J Mol Sci 2025;26:554. [PMID: 39859270 PMCID: PMC11765312 DOI: 10.3390/ijms26020554] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2024] [Revised: 12/30/2024] [Accepted: 01/08/2025] [Indexed: 01/27/2025]  Open
29
Liao C, Bai L, He T, Liang Q, Hu D, Lei S, He Y, Wang Y. Efficacy and Safety of Chemotherapy or EGFR-TKIs as First-Line Therapy in NSCLC Patients Harboring Non-Ex 20 Ins Uncommon EGFR Mutations: A Retrospective Study in China. Cancer Med 2025;14:e70542. [PMID: 39739938 DOI: 10.1002/cam4.70542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 12/07/2024] [Accepted: 12/13/2024] [Indexed: 01/02/2025]  Open
30
Zhang W, Zhang X, Zhao W, Guo Z, Liu X, Ye L, Chen Z, Xu K, Liu Y, Wang H, Zhao L, Zhang Q, Li Y, Chen X, He Y. What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis. BMC Pulm Med 2024;24:620. [PMID: 39695621 DOI: 10.1186/s12890-024-03438-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2024] [Accepted: 12/05/2024] [Indexed: 12/20/2024]  Open
31
Huang L, Kong W, Luo Y, Xie H, Liu J, Zhang X, Zhang G. Predicting epidermal growth factor receptor mutation status of lung adenocarcinoma based on PET/CT images using deep learning. Front Oncol 2024;14:1458374. [PMID: 39735601 PMCID: PMC11671303 DOI: 10.3389/fonc.2024.1458374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2024] [Accepted: 11/20/2024] [Indexed: 12/31/2024]  Open
32
Pang LL, Zhuang WT, Li JJ, Li B, Huang YH, Liao J, Li MD, Zhang L, Fang WF. Specifying the choice of EGFR-TKI based on brain metastatic status for advanced NSCLC with EGFR p.L861Q mutation. Neoplasia 2024;58:101073. [PMID: 39427513 PMCID: PMC11533552 DOI: 10.1016/j.neo.2024.101073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2024] [Revised: 10/11/2024] [Accepted: 10/15/2024] [Indexed: 10/22/2024]
33
Hernandez-Martinez JM, Guijosa A, Flores-Estrada D, Cruz-Rico G, Turcott J, Hernández-Pedro N, Caballé-Perez E, Cardona AF, Arrieta O. Real-World Survival Outcomes in Non-Small Cell Lung Cancer: The Impact of Genomic Testing and Targeted Therapies in a Latin American Middle-Income Country. JCO Glob Oncol 2024;10:e2400338. [PMID: 39637345 DOI: 10.1200/go-24-00338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2024] [Revised: 08/22/2024] [Accepted: 10/16/2024] [Indexed: 12/07/2024]  Open
34
Takashima K, Wakabayashi H, Murakami Y, Saiki A, Matsuzawa Y. Prognostic Factors in Japanese EGFR Mutation-Positive Non-Small-Cell Lung Cancer: A Real-World Single-Center Retrospective Cohort Study. Drugs Real World Outcomes 2024;11:603-615. [PMID: 39198334 PMCID: PMC11589054 DOI: 10.1007/s40801-024-00449-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/13/2024] [Indexed: 09/01/2024]  Open
35
Masciale V, Banchelli F, Grisendi G, Samarelli AV, Raineri G, Rossi T, Zanoni M, Cortesi M, Bandini S, Ulivi P, Martinelli G, Stella F, Dominici M, Aramini B. The molecular features of lung cancer stem cells in dedifferentiation process-driven epigenetic alterations. J Biol Chem 2024;300:107994. [PMID: 39547513 PMCID: PMC11714729 DOI: 10.1016/j.jbc.2024.107994] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2024] [Revised: 10/30/2024] [Accepted: 11/05/2024] [Indexed: 11/17/2024]  Open
36
Yang C, Qu J, Wu J, Cai S, Liu W, Deng Y, Meng Y, Zheng L, Zhang L, Wang L, Guo X. Single-cell dissection reveals immunosuppressive F13A1+ macrophage as a hallmark for multiple primary lung cancers. Clin Transl Med 2024;14:e70091. [PMID: 39601163 PMCID: PMC11600049 DOI: 10.1002/ctm2.70091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2024] [Revised: 10/22/2024] [Accepted: 11/01/2024] [Indexed: 11/29/2024]  Open
37
Chen CP, Hung TH, Hsu PC, Yeh CN, Huang WK, Pan YR, Hsiao YT, Lo CH, Wu CE. Synergistic effects of MK-1775 and gemcitabine on cytotoxicity in non-small cell lung cancer. Heliyon 2024;10:e40299. [PMID: 39605823 PMCID: PMC11600051 DOI: 10.1016/j.heliyon.2024.e40299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2024] [Revised: 10/29/2024] [Accepted: 11/07/2024] [Indexed: 11/29/2024]  Open
38
Liu A, Wang X, Wang L, Zhuang H, Xiong L, Gan X, Wang Q, Tao G. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR-mutated NSCLC: a network meta-analysis. BMC Cancer 2024;24:1390. [PMID: 39533233 PMCID: PMC11555867 DOI: 10.1186/s12885-024-13168-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2024] [Accepted: 11/07/2024] [Indexed: 11/16/2024]  Open
39
Jiang Z, Gu Z, Yu X, Cheng T, Liu B. Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Front Oncol 2024;14:1447678. [PMID: 39582541 PMCID: PMC11581962 DOI: 10.3389/fonc.2024.1447678] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Accepted: 09/25/2024] [Indexed: 11/26/2024]  Open
40
Priantti JN, Fujiwara Y, Aquino de Moraes FC, Michelon I, Castro C, Leighl NB, Cavalcante L, Addeo A, Bar J, Horita N, Cortellini A, Nassar AH, Vilbert M, Naqash AR. Safety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis. JCO Precis Oncol 2024;8:e2400331. [PMID: 39576954 DOI: 10.1200/po.24.00331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2024] [Revised: 09/12/2024] [Accepted: 10/11/2024] [Indexed: 11/24/2024]  Open
41
Hata A, Katakami N, Takase N, Kibata K, Yamanaka Y, Tamiya M, Mori M, Kijima T, Morita S, Sakai K, Nishio K. Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study. Lung Cancer 2024;197:107988. [PMID: 39393258 DOI: 10.1016/j.lungcan.2024.107988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2024] [Revised: 09/17/2024] [Accepted: 10/04/2024] [Indexed: 10/13/2024]
42
Malhotra J, Kim ES. How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer. JCO Oncol Pract 2024;20:1471-1480. [PMID: 39531842 DOI: 10.1200/op.24.00230] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2024] [Revised: 05/08/2024] [Accepted: 06/26/2024] [Indexed: 11/16/2024]  Open
43
Kenmotsu H, Sakai K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Koyama R, Masuda K, Hayashi H, Toyozawa R, Miura S, Sato Y, Nakagawa K, Yamamoto N, Nishio K, Takahashi T. Final Analysis Data and Exploratory Biomarker Analysis of a Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib Monotherapy for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: The WJOG9717L Study. JTO Clin Res Rep 2024;5:100716. [PMID: 39399795 PMCID: PMC11470244 DOI: 10.1016/j.jtocrr.2024.100716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2024] [Revised: 08/06/2024] [Accepted: 08/12/2024] [Indexed: 10/15/2024]  Open
44
Xiong Y, Wang L, Zhang W, Meng Y, Wang Y, Shen M, Zhou L, Li R, Lv Y, Wang S, Ren X, Liu L. First-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous NSCLC with EGFR-mutation. BMC Cancer 2024;24:1326. [PMID: 39472861 PMCID: PMC11520869 DOI: 10.1186/s12885-024-13084-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2024] [Accepted: 10/22/2024] [Indexed: 11/02/2024]  Open
45
Shong LYW, Deng JY, Kwok HH, Lee NCM, Tseng SCZ, Ng LY, Yee WKS, Lam DCL. Detection of EGFR mutations in patients with suspected lung cancer using paired tissue-plasma testing: a prospective comparative study with plasma ddPCR assay. Sci Rep 2024;14:25701. [PMID: 39465302 PMCID: PMC11514293 DOI: 10.1038/s41598-024-76890-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2024] [Accepted: 10/17/2024] [Indexed: 10/29/2024]  Open
46
Tong Y, Wan X, Yin C, Lei T, Gao S, Li Y, Du X. In-depth exploration of the focus issues of TKI combined with radiotherapy for EGFR-mutant lung adenocarcinoma patients with brain metastasis: a systematic analysis based on literature metrology, meta-analysis, and real-world observational data. BMC Cancer 2024;24:1305. [PMID: 39443874 PMCID: PMC11515526 DOI: 10.1186/s12885-024-13071-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Accepted: 10/17/2024] [Indexed: 10/25/2024]  Open
47
Hong Y, Zhuang W, Lai J, Xu H, He Y, Lin J, Shi Q, Chen S, Huang Z, Chen S, Lu D, Lin G, Huang Y. Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result. Sci Rep 2024;14:23115. [PMID: 39367090 PMCID: PMC11452669 DOI: 10.1038/s41598-024-73749-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2024] [Accepted: 09/20/2024] [Indexed: 10/06/2024]  Open
48
Batra U, Sharma M, Jain P, Narayan S, Jain A, Soni S, Nathany S. Indian experience of Afatinib for EGFR mutation-positive advanced lung adenocarcinoma a real-world retrospective study. Indian J Cancer 2024;61:671-675. [PMID: 39960693 DOI: 10.4103/ijc.ijc_893_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2020] [Accepted: 02/07/2021] [Indexed: 05/09/2025]
49
Yoh K, Azuma K, Hayashi H, Nishio M, Chikamori K, Ichihara E, Watanabe Y, Asato T, Kitagawa T, Fram RJ, Ohe Y. A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations. Int J Clin Oncol 2024;29:1461-1474. [PMID: 39190099 PMCID: PMC11420270 DOI: 10.1007/s10147-024-02588-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2024] [Accepted: 07/15/2024] [Indexed: 08/28/2024]
50
Ni H, Wang Z, Tang Y, Lu J, Zhu Z, Qiu Y, Chen Z, Wang Z. Tyrosine kinase inhibitors in the treatment of leptomeningeal carcinomatosis. Cell Biol Int 2024;48:1450-1462. [PMID: 39136350 DOI: 10.1002/cbin.12230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Revised: 06/28/2024] [Accepted: 07/31/2024] [Indexed: 10/19/2024]
PrevPage 1 of 32 123453132Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA